{"doi":"10.2217/fon-2020-1202","title":"First-Line Pembrolizumab with or Without Platinum Doublet Chemotherapy in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%","abstract":null,"journal":"Future Oncology","year":2021,"id":649246,"datarank":0.42498200160843247,"base_score":2.833213344056216,"endowment":2.833213344056216,"self_citation_contribution":0.42498200160843247,"citation_network_contribution":0.0,"self_endowment_contribution":0.42498200160843247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":595047,"name":"C. Chouaïd","orcid":"0000-0002-4290-5524","position":1,"is_corresponding":false},{"id":1650267,"name":"Maurice Pérol","orcid":null,"position":2,"is_corresponding":false},{"id":616259,"name":"Benjamin Besse","orcid":"0000-0001-5090-8189","position":3,"is_corresponding":false},{"id":132968,"name":"Laurent Greillier","orcid":null,"position":4,"is_corresponding":false},{"id":1013708,"name":"Olivier Bylicki","orcid":"0000-0001-8683-0969","position":5,"is_corresponding":false},{"id":1577827,"name":"Charles Ricordel","orcid":null,"position":6,"is_corresponding":false},{"id":1577825,"name":"Florian Guisier","orcid":"0000-0002-8166-7303","position":7,"is_corresponding":false},{"id":1692422,"name":"Radj Gervais","orcid":null,"position":8,"is_corresponding":false},{"id":1577833,"name":"Roland Schott","orcid":"0000-0002-7735-5366","position":9,"is_corresponding":false},{"id":1692425,"name":"Jean-Bernard Auliac","orcid":null,"position":10,"is_corresponding":false},{"id":1692427,"name":"Gilles Robinet","orcid":null,"position":11,"is_corresponding":false},{"id":1692429,"name":"Chantal Decroisette","orcid":null,"position":12,"is_corresponding":false},{"id":1692413,"name":"Renaud Descourt","orcid":"0000-0003-2385-9507","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"First-Line Pembrolizumab with or Without Platinum Doublet Chemotherapy in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%","abstract":"Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer without EGFR mutations or ALK rearrangements, regardless of PD-L1 expression status. A study comparing chemotherapy plus pembrolizumab versus pembrolizumab alone has never been performed in patients with PD-L1 ≥50%. The aim of this trial is to perform such a comparison as first-line treatment in patients not eligible for locally advanced treatment who have expression of PD-L1 on ≥50% of tumor cells. The expected results are a reduction in the risk of early progression. A higher objective tumor response is also expected with the combination of chemotherapy and pembrolizumab compared with pembrolizumab alone. The study will allow a direct comparison of the proportion of patients who derive long-term benefit from the treatment. Clinical trial number: EudraCT (2020-002626-86); ClinicalTrials.gov (NCT04547504).","is_dataset_classified":null,"base_score":2.833213344056216,"endowment":2.833213344056216,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34156285","pmcid":null,"openalex_id":"https://openalex.org/W3175277114","authors":[],"funders":[],"total_grants":0,"fwci":0.7298,"citation_percentile":0.72818646,"influential_citations":0,"citation_trend":[{"year":2021,"count":2},{"year":2022,"count":2},{"year":2023,"count":3},{"year":2024,"count":2},{"year":2025,"count":6},{"year":2026,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fon-2020-1202","host_type":"publisher"},{"url":"https://doi.org/10.2217/fon-2020-1202","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/34156285","host_type":"repository"},{"url":"https://inria.hal.science/hal-03526346","host_type":"repository"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Lung Cancer Treatments and Mutations","Colorectal Cancer Treatments and Studies"],"mesh_terms":["Progression-Free Survival","Adult","Antineoplastic Combined Chemotherapy Protocols","Carcinoma, Non-Small-Cell Lung","Female","Follow-Up Studies","Humans","Lung","Lung Neoplasms","Male","Middle Aged","Prospective Studies","Multicenter Studies as Topic","Randomized Controlled Trials as Topic","Clinical Trials, Phase III as Topic","Disease Progression","B7-H1 Antigen","Antibodies, Monoclonal, Humanized","Response Evaluation Criteria in Solid Tumors"],"keywords":["Pembrolizumab","Medicine","Platinum","Chemotherapy","Lung cancer","Oncology","PD-L1","Cancer research","Internal medicine","Immunotherapy","Cancer","Biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T03:25:23.656482Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}